DNA

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metastatic Castration-Resistant Prostate Cancer

Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused…

7 months ago

Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a…

7 months ago

Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs Healthcare C-Suite Unscripted Conference

WALTHAM, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a…

7 months ago

Harpoon Therapeutics Strengthens Leadership Team

James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec.…

7 months ago

HSG Advisors’ Chief Strategy Officer DJ Sullivan Honored by Becker’s Hospital Review as an Emerging Leader in Healthcare

Sullivan earns a spot on Becker's 2023 "Emerging leaders: 37 healthcare company leaders under 40" listLOUISVILLE, KY / ACCESSWIRE /…

7 months ago

MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads

Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridementYAVNE, Israel,…

7 months ago

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three…

7 months ago

Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF

TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage…

7 months ago

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

Independent DSMB recommends continuing clinical trial of Berubicin without modificationEnrollment expected to be complete in early Q1 2024HOUSTON, TX /…

7 months ago

Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024

LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on…

7 months ago